Doximity DOCS 深 沪
等待开盘 12-13 09:30:00 美东时间
43.85
-0.280
-0.63%
华盛通- 最 高44.865
- 今 开43.88
- 成交量 309.73万股
- 最 低 43.60
- 昨 收 44.13
- 总市值 82.44亿
- 52周最高 85.21
- 市盈率 静 39.53
- 换手率 1.65%
- 52周最低 43.60
- 委 比 43.90%
- 总股本 1.88亿
- 历史最高 107.79
- 量 比 0.69
- 振 幅 2.87%
- 历史最低 19.71
- 每 手 1
- 风险率 7.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Barclays Initiates Coverage On Doximity with Overweight Rating, Announces Price Target of $63
Barclays analyst Glen Santangelo initiates coverage on Doximity (NYSE:DOCS) with a Overweight rating and announces Price Target of $63.
12-09 23:40
How Do Investors Really Feel About Doximity Inc?
Doximity Inc's (NYSE:DOCS) short interest as a percent of float has fallen 8.7%...
11-27 02:00
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
Raymond James Upgrades Doximity to Strong Buy, Lowers Price Target to $65
Raymond James analyst Brian Peterson upgrades Doximity (NYSE:DOCS) from Outperform to Strong Buy and lowers the price target from $75 to $65.
11-22 00:57
Doximity upgraded at Raymond James on improving long-term growth visibility
Raymond James upgraded Doximity (DOCS) to strong buy from outperform, saying that the digital platform for doctors with a "current risk/reward at 25x [free cash flow] looking too compelling to ignore....
11-22 00:15
Preview: Veeva Sys's Earnings
Veeva Sys (NYSE:VEEV) is gearing up to announce its quarterly earnings on Thurs...
11-19 22:02
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Jim Cramer: Don't Buy This Health Care Stock Yet, It Is 'Still Too Expensive'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended waiting and not buying Doximity, adding that it is "still too expensive."
11-13 21:20
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
